Puma Biotechnology Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
All right. Welcome, everyone, to the afternoon session of the BofA virtual health care conference.
I'm Scott Puckhaber, one of the biopharma analysts here at BofA. We're really thrilled to have Puma Biotech present today and have the CEO, Alan Auerbach, with us.
So with that, I'll hand it over to Alan for his presentation. Alan?
Great. Thank you very much, Scott, and thank you, everyone, for attending the Puma Biotechnology presentation.
Moving to Slide #2. Just a reminder that I'm going to be making forward-looking statements.
So on Slide 3, you can see the product pipeline for Puma. This consists of our drug neratinib, which is in several different indications, as you can see on the slide. We are currently approved in what we refer to as the extended adjuvant HER2-positive breast cancer space and that is based on the ExteNET trial, which was our Phase III
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
